دسترسی یکساله به بیش از ۵۰۰ ژورنال روز جهان موجود در سامانه
-
http://medilib.ir
- ﻣﺪﺕ ﺯﻣﺎﻥ : 365 ﺭﻭﺯ
قیمت : 3,800,000 تومان- قیمت ویژه : 1,900,000تومان
Thanks to referees 2020
doi : 10.1016/j.annonc.2020.10.482
Volume 32, Issue 1, January 2021, Pages 1-3
PARP inhibition in homologous-recombination-deficient early-stage breast cancer
doi : 10.1016/j.annonc.2020.11.001
Volume 32, Issue 1, January 2021, Pages 4-5
TOSCA—a delicious Swedish almond cake, an Italian opera and an Italian trial with important new data
B. Glimelius
doi : 10.1016/j.annonc.2020.10.598
Volume 32, Issue 1, January 2021, Pages 6-8
Expanding the nanotherapeutic toolbox for non-small-cell lung cancer
J. Jee, B.T. Li
doi : 10.1016/j.annonc.2020.11.010
Volume 32, Issue 1, January 2021, Pages 9-11
Is there a role for novel TKI/ICI combinations in metastatic renal cell carcinoma? Definitely maybe
L. Meza, P.G. Bergerot, N. Agarwal, S.K. Pal
doi : 10.1016/j.annonc.2020.10.481
Volume 32, Issue 1, January 2021, Pages 12-14
Data protection and research in the European Union: a major step forward, with a step back
P.G. Casali, M. Vyas, European Society for Medical Oncology (ESMO)
doi : 10.1016/j.annonc.2020.10.472
Volume 32, Issue 1, January 2021, Pages 15-19
Cautionary tails
J.C. Del Paggio, I.F. Tannock
doi : 10.1016/j.annonc.2020.10.469
Volume 32, Issue 1, January 2021, Pages 20-22
Chronic lymphocytic leukaemia: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up
B. Eichhorst, T. Robak, E. Montserrat, P. Ghia, ... U. Mey
doi : 10.1016/j.annonc.2020.09.019
Volume 32, Issue 1, January 2021, Pages 23-33
Side-effect management of chimeric antigen receptor (CAR) T-cell therapy
M.-L. Schubert, M. Schmitt, L. Wang, C.A. Ramos, ... P. Dreger
doi : 10.1016/j.annonc.2020.10.478
Volume 32, Issue 1, January 2021, Pages 34-48
Neoadjuvant paclitaxel/olaparib in comparison to paclitaxel/carboplatinum in patients with HER2-negative breast cancer and homologous recombination deficiency (GeparOLA study)
P.A. Fasching, T. Link, J. Hauke, F. Seither, ... S. Loibl
doi : 10.1016/j.annonc.2020.10.471
Volume 32, Issue 1, January 2021, Pages 49-57
The efficacy and toxicity of olaparib as combination therapy in early breast cancer (BC) patients with homologous recombinant deficiency (HRD) [score high and/or germline (g) or tumour (t) BRCA1/2 mutation] is not well described. GeparOLA (ClinicalTrials.gov, NCT02789332) investigated olaparib in combination with paclitaxel in HER2-negative early BC with HRD.
Assessment of structural chromosomal instability phenotypes as biomarkers of carboplatin response in triple negative breast cancer: the TNT trial
O. Sipos, H. Tovey, J. Quist, S. Haider, ... A. Grigoriadis
doi : 10.1016/j.annonc.2020.10.475
Volume 32, Issue 1, January 2021, Pages 58-65
In the TNT trial of triple negative breast cancer (NCT00532727), germline BRCA1/2 mutations were present in 28% of carboplatin responders. We assessed quantitative measures of structural chromosomal instability (CIN) to identify a wider patient subgroup within TNT with preferential benefit from carboplatin over docetaxel.
Overall survival with 3 or 6 months of adjuvant chemotherapy in Italian TOSCA phase 3 randomised trial
F. Petrelli, E. Rulli, R. Labianca, S. Lonardi, ... A. Sobrero
doi : 10.1016/j.annonc.2020.10.477
Volume 32, Issue 1, January 2021, Pages 66-76
Oxaliplatin-based adjuvant chemotherapy is the standard treatment of high-risk colon cancer (CC). A shorter duration (3 months) can achieve a similar outcome [in terms of relapse-free survival (RFS)] to a longer duration. This study reports the overall survival (OS) analysis of the three or six colon adjuvant (TOSCA) phase III study. It assessed different adjuvant chemotherapy durations in patients with resected high-risk stage II and stage III CC.
Oxaliplatin-based adjuvant chemotherapy duration (3 versus 6 months) for high-risk stage II colon cancer: the randomized phase III ACHIEVE-2 trial
K. Yamazaki, T. Yamanaka, M. Shiozawa, D. Manaka, ... T. Yoshino
doi : 10.1016/j.annonc.2020.10.480
Volume 32, Issue 1, January 2021, Pages 77-84
Oxaliplatin-based adjuvant chemotherapy may be associated with debilitating peripheral sensory neuropathy (PSN) in patients with high-risk stage II colon cancer. This open-label, multicenter, randomized phase III trial was conducted as a prospective pooled analysis to investigate the non-inferiority of 3 versus 6 months of adjuvant oxaliplatin-based chemotherapy.
Comparing nanoparticle polymeric micellar paclitaxel and solvent-based paclitaxel as first-line treatment of advanced non-small-cell lung cancer: an open-label, randomized, multicenter, phase III trial
M. Shi, A. Gu, H. Tu, C. Huang, ... Y.L. Wu
doi : 10.1016/j.annonc.2020.10.479
Volume 32, Issue 1, January 2021, Pages 85-96
Polymeric micellar paclitaxel (pm-Pac) is a novel Cremophor EL-free, nanoparticle micellar formulation of paclitaxel. We aimed to compare the efficacy and safety between pm-Pac plus cisplatin and solvent-based paclitaxel (sb-Pac) plus cisplatin in advanced non-small-cell lung cancer (NSCLC).
TiNivo: safety and efficacy of tivozanib-nivolumab combination therapy in patients with metastatic renal cell carcinoma
L. Albiges, P. Barthélémy, M. Gross-Goupil, S. Negrier, ... B. Escudier
doi : 10.1016/j.annonc.2020.09.021
Volume 32, Issue 1, January 2021, Pages 97-102
Treatment with tivozanib, a highly selective and potent vascular endothelial growth factor receptor tyrosine kinase inhibitor, has demonstrated single-agent efficacy in advanced renal cell carcinoma (RCC) along with minimal off-target toxicities and a favorable adverse event (AE) profile. We report final results from TiNivo, a phase Ib/II study of tivozanib combined with nivolumab.
A meta-analysis of reversion mutations in BRCA genes identifies signatures of DNA end-joining repair mechanisms driving therapy resistance
L. Tobalina, J. Armenia, E. Irving, M.J. O'Connor, J.V. Forment
doi : 10.1016/j.annonc.2020.10.470
Volume 32, Issue 1, January 2021, Pages 103-112
Germline mutations in the BRCA1 or BRCA2 (BRCA) genes predispose to hereditary breast and ovarian cancer and, mostly in the case of BRCA2, are also prevalent in cases of pancreatic and prostate malignancies. Tumours from these patients tend to lose both copies of the wild-type BRCA gene, which makes them exquisitely sensitive to platinum drugs and poly(ADP-ribose) polymerase inhibitors (PARPi), treatments of choice in these disease settings. Reversion secondary mutations with the capacity of restoring BRCA protein expression have been documented in the literature as bona fide mechanisms of resistance to these treatments.
Seroconversion in patients with cancer and oncology health care workers infected by SARS-CoV-2
A. Marra, D. Generali, P. Zagami, V. Cervoni, ... G. Curigliano
doi : 10.1016/j.annonc.2020.10.473
Volume 32, Issue 1, January 2021, Pages 113-119
Patients with cancer have high risk for severe complications and poor outcome to severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2)-related disease [coronavirus disease 2019 (COVID-19)]. Almost all subjects with COVID-19 develop anti-SARS-CoV-2 immunoglobulin G (IgG) within 3 weeks after infection. No data are available on the seroconversion rates of cancer patients and COVID-19.
Local delivery of CAR T cells targeting fibroblast activation protein is safe in patients with pleural mesothelioma: first report of FAPME, a phase I clinical trial
S. Hiltbrunner, C. Britschgi, P. Schuberth, L. Bankel, ... A. Curioni-Fontecedro
doi : 10.1016/j.annonc.2020.10.474
Volume 32, Issue 1, January 2021, Pages 120-121
COVID-19-associated pancytopenia can be self-limiting and does not necessarily warrant bone marrow biopsy for the purposes of SARS-CoV-2 diagnostics
D.S. Hersby, T.H. Do, A.O. Gang, T.H. Nielsen
doi : 10.1016/j.annonc.2020.09.020
Volume 32, Issue 1, January 2021, Pages 121-123
Prognostic models: clinical impact now within reach
A. Bauer-Mehren, D. Rüttinger
doi : 10.1016/j.annonc.2020.10.467
Volume 32, Issue 1, January 2021, Pages 123-124
The cost–benefit ratio of a smile
F. Avanzini
doi : 10.1016/j.annonc.2020.09.022
Volume 32, Issue 1, January 2021, Pages 124-125
Corrigendum to “Inhibiting fibroblast growth factor receptors in cancer – the next generation”: Annals of Oncology (2020) volume 31, 1285-1286
M. Schuler
doi : 10.1016/j.annonc.2020.10.593
Volume 32, Issue 1, January 2021, Page 126
